We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




AI Model Detects Cancer at Lightning Speed through Sugar Analyses

By LabMedica International staff writers
Posted on 04 Jul 2024
Print article
Image: The mass spectrometer can detect different structures of the sugar molecules, called glycans, in cells (Photo courtesy of Lundbergs forskningsstiftelse/Magnus Gotander)
Image: The mass spectrometer can detect different structures of the sugar molecules, called glycans, in cells (Photo courtesy of Lundbergs forskningsstiftelse/Magnus Gotander)

Glycans, which are structures made up of sugar molecules within cells, can be analyzed using mass spectrometry. This technique is particularly useful because these sugar structures can reveal the presence of various cancer types within cells. However, interpreting the data from mass spectrometry, specifically, the fragmentation patterns of glycans, requires meticulous human analysis. This detailed scrutiny can take from several hours to days per sample and is only reliably performed by a handful of highly skilled experts globally, as it involves complex, learned detective work over many years. This need for expert analysis creates a significant bottleneck in utilizing glycan analysis for applications like cancer detection, especially when numerous samples need examination. Researchers have now introduced an artificial intelligence (AI) model that enhances the ability to detect cancer through sugar molecule analysis, proving to be both quicker and more effective than the traditional semi-manual approaches.

The AI model, named Candycrunch, was trained by researchers at the University of Gothenburg (Gothenburg, Sweden) using a vast database containing over 500,000 examples of various fragmentations and associated structures of sugar molecules. This extensive training has equipped Candycrunch to accurately determine the precise structure of sugars in a sample in 90% of cases, aiming to soon match the accuracy levels seen in the sequencing of other biological sequences like DNA, RNA, and proteins. The AI model described in a scientific article published in Nature Methods automates glycan analysis and completes it in just a few seconds. Moreover, Candycrunch can identify sugar structures that are typically overlooked by human analysts due to their low concentrations. Due to its speed and precision, Candycrunch significantly speeds up the identification of glycan-based biomarkers, which are crucial for diagnosing and predicting cancer. Thus, the model holds promise in aiding researchers to discover new glycan-based biomarkers for cancer.

“We believe that glycan analyses will become a bigger part of biological and clinical research now that we have automated the biggest bottleneck,” said Daniel Bojar, Associate Senior Lecturer in Bioinformatics at the University of Gothenburg.

Related Links:
University of Gothenburg

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article
77 ELEKTRONIKA

Channels

Hematology

view channel
Image: The new Yumizen H550E (autoloader), H500E CT (closed tube), and Yumizen H500E OT (open tube) (Photo courtesy of HORIBA)

New Hematology Analyzers Deliver Combined ESR and CBC/DIFF Results in 60 Seconds

HORIBA (Kyoto, Japan) has expanded its line of compact hematology analyzers by introducing new models that incorporate Erythrocyte Sedimentation Rate (ESR) measurement capabilities. The newly launched... Read more

Pathology

view channel
Image: The new test helps differentiate a B-cell cancer from a normal, reactive immune response (Photo courtesy of Roche)

New Highly-Sensitive Test to Help More Easily Diagnose B-Cell Lymphoma

B-cell lymphoma, a cancer primarily originating in the lymphatic system, represents about 85% of non-Hodgkin lymphoma (NHL) diagnoses. NHL ranks as the tenth most prevalent cancer globally, claiming over... Read more

Industry

view channel
Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)

Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing

Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.